WAIKOLOA, Hawaii — Diagnosing and treating ocular surface disease preoperatively is one of the elements that contribute to elevated patient satisfaction postoperatively, Marjan Farid, MD, said at Hawaiian Eye 2022.
“We know that 50% of patients, at least, who come in for cataract surgery are asymptomatic, but at least 80% of those patients have at least one sign of dry eye
NEW ORLEANS — Patients with dry eye disease saw improvements in symptoms and signs after treatment with varenicline nasal spray, according to a study presented at the American Academy of Ophthalmology meeting. Marjan Farid, MD, said Tyrvaya (varenicline solution, Oyster Point Pharma), formerly known as OC-01, is a cholinergic agonist that leads to an increase in basal tear production
IACTA Pharmaceuticals and Pharmaleads to Develop the World s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
News provided by
Share this article
-
License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies
IRVINE, Calif., PARIS, HONG KONG, Jan. 7, 2021 /PRNewswire/ IACTA Pharmaceuticals, Inc. ( IACTA ) and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads Dual Enkephalinase Inhibitors (DENKI
®), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain.